David Scadden Net Worth

The estimated Net Worth of David Scadden is at least $429 Thousand dollars as of 13 June 2024. David Scadden owns over 3,388 units of Editas Medicine Inc stock worth over $58,526 and over the last 7 years he sold EDIT stock worth over $0. In addition, he makes $370,652 as Independent Director at Editas Medicine Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

David Scadden EDIT stock SEC Form 4 insiders trading

David has made over 7 trades of the Editas Medicine Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he exercised 3,388 units of EDIT stock worth $12,807 on 13 June 2024.

The largest trade he's ever made was buying 6,600 units of Editas Medicine Inc stock on 25 June 2018 worth over $99,000. On average, David trades about 812 units every 91 days since 2017. As of 13 June 2024 he still owns at least 15,483 units of Editas Medicine Inc stock.

You can see the complete history of David Scadden stock trades at the bottom of the page.

David Scadden biography

Dr. David T. Scadden M.D. serves as Independent Director of the Company. Dr. Scadden is the Gerald and Darlene Jordan Professor of Medicine at Harvard University, a position he has held since 2006. Since 1995, Dr. Scadden has practiced at the Massachusetts General Hospital, where he founded and directs the Center for Regenerative Medicine and directed the Hematologic Malignancies Center of the MGH Cancer Center for 10 years. Dr. Scadden co-founded and co-directs the Harvard Stem Cell Institute and is Chairman emeritus and Professor of the Harvard University Department of Stem Cell and Regenerative Biology. He is a member of the National Academy of Medicine and the American Academy of Arts and Sciences and a Fellow of the American College of Physicians and the American Academy for the Advancement of Science. He is a former affiliate member of the Broad Institute of Harvard and the Massachusetts Institute of Technology and is a former member of the Board of External Experts for the National Heart, Lung and Blood Institute, the Board of Scientific Counselors for the National Cancer Institute and Board of Directors of the International Society for Stem Cell Research. Dr. Scadden has served on the boards of Agios since May 2017 and Magenta Therapeutics, Inc., a public biotechnology company, since November 2016, where he is a scientific founder, and private biotechnology companies LifeVault Bio and Clear Creek Bio, Inc. since May 2017 and February 2017, respectively, and is a scientific founder of Fate Therapeutics, Inc., a public biotechnology company. Dr. Scadden holds a B.A. from Bucknell University in English, an M.D. from Case Western Reserve University and holds honorary degrees, including an A.M. from Harvard Medical School, an Sc.D. from Bucknell University, D. Sci from Case Western Reserve University and an M.D. from Lund University in Sweden. Scadden is qualified to serve on our Board due to his scientific expertise in the fields of hematology and oncology.

What is the salary of David Scadden?

As the Independent Director of Editas Medicine Inc, the total compensation of David Scadden at Editas Medicine Inc is $370,652. There are 4 executives at Editas Medicine Inc getting paid more, with Cynthia Collins having the highest compensation of $14,489,700.

How old is David Scadden?

David Scadden is 67, he's been the Independent Director of Editas Medicine Inc since 2019. There are no older and 16 younger executives at Editas Medicine Inc.

What's David Scadden's mailing address?

David's mailing address filed with the SEC is C/O AGIOS PHARMACEUTICALS, INC., 88 SIDNEY STREET, CAMBRIDGE, MA, 02139.

Insiders trading at Editas Medicine Inc

Over the last 9 years, insiders at Editas Medicine Inc have traded over $73,429,036 worth of Editas Medicine Inc stock and bought 241,700 units worth $4,697,822 . The most active insiders traders include Andrew A. F. Hack, Kevin P Starr, and Kevin Bitterman. On average, Editas Medicine Inc executives and independent directors trade stock every 22 days with the average trade being worth of $126,770. The most recent stock trade was executed by Baisong Mei on 4 September 2024, trading 518 units of EDIT stock currently worth $1,772.

What does Editas Medicine Inc do?

unlocking the promise of genome editing to deliver life-changing medicines. editas medicine's mission is to translate its genome editing technology into a novel class of human therapeutics that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.

Complete history of David Scadden stock trades at Agios Pharmaceuticals Inc, Editas Medicine Inc, and Magenta Therapeutics Inc

Editas Medicine Inc executives and stock owners

Editas Medicine Inc executives and other stock owners filed with the SEC include:

• Cynthia Collins,
  President, Chief Executive Officer, Director
• Charles Albright,
  Executive Vice President, Chief Scientific Officer
• Dr. Bruce E. Eaton Ph.D.,
  Exec. VP & Chief Bus. Officer
• Michelle Robertson,
  CFO, Principal Accounting Officer, Treasurer & Assistant Sec.
• David Scadden,
  Independent Director
• James Mullen,
  Independent Chairman of the Board
• Jessica Hopfield,
  Independent Director
• Andrew Hirsch,
  Independent Director
• Dr. Lisa A. Michaels M.D.,
  Exec. VP & Chief Medical Officer
• Akshay Vaishnaw,
  Independent Director
• James C. Mullen,
  Chairman, Pres & CEO
• Lisa Michaels,
  Executive Vice President, Chief Medical Officer
• Mark Mullikin,
  Investor Relations Officer
• Gad Berdugo,
  Chief Business Officer
• Harry Gill,
  Senior Vice President - Operations
• Michelle Robertson,
  Chief Financial Officer
• Dr. Gilmore O'Neill,
  Pres & CEO
• Charlene Stern J.D., Ph.D.,
  Exec. VP & Gen. Counsel
• Ron Moldaver,
  Investor Relations
• Dr. J. Keith Joung M.D., Ph.D.,
  Co-Founder & Scientific Advisory Board Member
• Dr. George McDonald Church Ph.D.,
  Co-Founder & Scientific Advisory Board Member
• Charlene Stern,
  Sr. VP & Chief Legal Officer
• Dr. Mark S. Shearman,
  Exec. VP & Chief Scientific Officer
• Harry R. Gill III,
  Sr. VP of Operations
• Dr. David R. Liu,
  Co-Founder & Scientific Advisory Board Member
• Dr. J. Keith Joung,
  Co-Founder & Scientific Advisory Board Member
• Dr. George M. Church,
  Co-Founder & Scientific Advisory Board Member
• Dr. Feng Zhang,
  Co-Founder & Scientific Advisory Board Member
• Douglas G. Cole,
  Director
• Katrine Bosley,
  President and CEO
• Kevin P Starr,
  10% owner
• Alexis Borisy,
  Director
• Alexandra Glucksmann,
  Chief Operating Officer
• Venture Management Co. Vi, ...,
  
• Ventures Fund Iv, L.P.Flags...,
  
• Kevin Bitterman,
  Director
• Gerald Frank Cox,
  Chief Medical Officer
• Ventures Fund Iv, L.P.Flags...,
  
• John Mendlein,
  Director
• Boris Nikolic,
  Director
• Andrew A. F. Hack,
  Chief Financial Officer
• Rock Ventures Iii, L.P.Thir...,
  
• Llc Bng0,,
  10% owner
• Bernadette Connaughton,
  Director
• Elliott M. Levy,
  Director
• Vickesh Myer,
  Chief Technology Officer
• Global Investors Lp Viking ...,
  
• Global Performance Llc Viki...,
  
• James E Deerfield Mgmt Iii,...,
  
• Baisong Mei,
  EVP, CHIEF MEDICAL OFFICER
• Mark S Shearman,
  EVP, CHIEF SCIENTIFIC OFFICER
• Meeta Chatterjee,
  Director
• Bruce Eaton,
  EVP, CBO AND CTO
• Emma Reeve,
  Director
• Erick Lucera,
  EVP, CHIEF FINANCIAL OFFICER
• Gilmore Neil O'neill,
  CEO
• Linda Burkly,
  EVP, CHIEF SCIENTIFIC OFFICER